IMR Press / FBL / Volume 28 / Issue 6 / DOI: 10.31083/j.fbl2806108
Cite this article
Nanoparticles: Properties, applications and toxicities
60
Downloads
241
Views
Submit to FBL
Review for FBL
Apply for Special Issue
  • Academic Editor
    Graham Pawelec
Chapters
Figures
References
Abstract
Keywords
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Availability of Data and Materials
Author Contributions
Ethics Approval and Consent to Participate
Acknowledgment
Funding
Conflict of Interest
References
Open Access Original Research
Protective Effect of Unfractionated Heparin on Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Neonatal Mice via the JAK2/STAT3 Signaling Pathway
Jing Xiong1,2,3,4,5, Qing Ai1,2,3,4,5, Lei Bao1,2,3,4,5, Yuan Shi1,2,3,4,5,*
Show Less
1 Neonatal Diagnosis and Treatment Center of Children's Hospital of Chongqing Medical University, 400014 Chongqing, China
2 National Clinical Research Center for Child Health and Disorders, 400014 Chongqing, China
3 Ministry of Education Key Laboratory of Child Development and Disorders, 400014 Chongqing, China
4 China International Science and Technology Cooperation Base of Child Development and Critical Disorders, 400014 Chongqing, China
5 Chongqing Key Laboratory of Pediatrics, 400014 Chongqing, China
*Correspondence: shiyuan@hospital.cqmu.edu.cn (Yuan Shi)
Front. Biosci. (Landmark Ed) 2023, 28(6), 108; https://doi.org/10.31083/j.fbl2806108
Submitted: 20 October 2022 | Revised: 31 December 2022 | Accepted: 16 January 2023 | Published: 8 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Download PDF
Brower Figures
Cite
Abstract

Background: Neonatal acute respiratory distress syndrome (ARDS) is a clinical disorder characterized by excessive acute inflammatory response in lung parenchyma and has high morbidity and mortality. However, the therapeutic treatments are still lacking. The aim of this study is to evaluate the role of unfractionated heparin in neonatal ARDS and explore the underlying mechanism of its effects. Methods: To conduct the ARDS model, the mouse pups were treated by intraperitoneal injection of lipopolysaccharide (LPS) (10 mg/kg). For unfractionated heparin intervention group, C57BL/6 mouse pups received a single subcutaneous injection of unfractionated heparin (400 IU/kg) 30 minutes prior to LPS. The survival rate was recorded for each group. Histological analysis was used to evaluate lung injury. MPO (myeloperoxidase) concentration level in lung tissues and extracellular histones in serum were detected by enzyme linked immunosorbent assay (ELISA). A commercially available kit was used to detect inflammatory cytokine levels in serum. Real time quantitative polymerase chain reaction (qPCR) and western blot were used to detect the mRNA and protein in the JAK2/STAT3 signaling pathway, respectively. Results: Intervention of unfractionated heparin significantly increased the survival rate of mouse pups with ARDS, restored lung architecture, inhibited neutrophil infiltration as evidenced by reduced MPO concentration, and attenuated the LPS-induced inflammatory responses, characterized by the down-regulation of proinflammatoy factors and up-regulation of anti-inflammatory factor when compared with the ARDS group. In addition, the concentration of extracellular histones, which have been proven to be mediated in the pathogenesis of ARDS, was diminished by unfractionated heparin. Moreover, the protein expressions of p-JAK2 (Y1007/1008) and p-STAT3 (Y705) in the ARDS group were remarkably up-regulated, which were reversed by unfractionated heparin. Conclusions: Unfractionated heparin protects LPS-induced ARDS via inhibiting JAK2/STAT3 pathway in neonatal mice, which might present a novel therapeutic target for ARDS of neonates.

Keywords
acute respiratory distress syndrome
unfractionated heparin
JAK2/STAT3 pathway
mice
newborn
1. Introduction

Firstly described in 1967 by Ashbaugh et al. [1], acute respiratory distress syndrome (ARDS) is characterized by acute diffuse, bilateral pulmonary injury resulting in increased alveolocapillary permeability, interstitial and alveolar haemorrhage, and the development of nonhydrostatic pulmonary edema in patients. In 2017, De Luca et al. [2] proposed the Monteux definition for neonatal ARDS. Like ARDS in children and adults, neonatal ARDS has its own peculiarities, including infectious triggers, incidence, and mortality. Although great improvement has been made in ARDS of neonates these years, it remains a life-threatening problem with high morbidity and mortality [3]. A multi-center trial of China reported that the mortality rate of newborns with severe ARDS and gestational age more than 36 weeks was 25.2% [4]. One of common pathological factors of ARDS is the systemic inflammation accompanied by accumulation of inflammatory cells and release of inflammatory cytokines [5, 6]. However, the pathogenesis of neonatal ARDS remains unclear. Treatments for neonatal ARDS including ventilation strategies (e.g., high-frequency oscillatory ventilation (HFOV)), supportive cares, and pharmacotherapies (e.g., surfactant, inhaled nitric oxide, and neutrophil elastase inhibitor). However, the therapeutic effects of these pharmacotherapies for ARDS were inconsistent in most of the clinical trials. And the drugs that target a variety of biological pathways, including inflammation, endothelial injury, and epithelial injury, have been verified to be inconsistently effective [7].

Therapeutic doses of heparin has been applied in patients with intravascular coagulation and sepsis for more than 20 years [8]. Some studies have showed that heparin has both anticoagulant effects and anti-inflammatory effects in acute lung injury models [9, 10]. Recently, more and more studies focused on heparin therapy on ARDS in experimental models or in patients. Wang et al. [11] noted that unfractionated heparin ameliorated the endotoxemia-induced lung injury in rats. Dixon et al. [12] reported that nebulised heparin limited progression of lung injury in patients with ARDS. In addition, heparin was reported to exert anti-inflammatory effect in acute lung injury (ALI) of rats via inhibiting transforming growth factor-β1 (TGF-β1) and Smad activities [13]. Heparin was also reported to inhibit the nuclear factor kappa B (NF-κB) pathway in monocytes treated with lipopolysaccharide (LPS) [14, 15]. However, the mechanisms by which heparin exerts its therapeutic effects on ARDS have remained elusive.

The Janus kinase/signal transducer and activator of the transcription (JAK/STAT) signaling pathway is mediated in a variety of cellular processes such as inflammation, apoptosis, and development [16], and JAK2/STAT3 is a proinflammation and apoptosis pathway [17]. JAK2 is a nonreceptor tyrosine kinase, and the phosphorylation of the tyrosine 1007 (Y1007) and tyrosine 1008 (Y1008) residues plays a regulatory role in the function of JAK2 [18, 19]. Tyrosine 705 (Y705) is a major phosphorylation site of STAT3, and activation of STAT3 on Y705 is mediated by JAK upon stimulation of the heterodimeric glycoprotein 130 (gp130)/cytokine-specific receptor [20]. JAK2/STAT3 pathway has been reported to be inhibited in ALI of mice [21, 22, 23]. Since JAK2/STAT3 pathway is involved in the pathogenesis of ARDS and regulating the coagulation activity and inflammatory response in lungs [24], and heparin exerts both anti-coagulant and anti-inflammatory properties, we hypothesized that unfractionated heparin might attenuate LPS-induced neonatal ARDS through inhibition of JAK2/STAT3 signaling pathway. The present study was designed to verify the hypothesis that unfractionated heparin protects neonatal mice against LPS-induced lung injury by suppressing the JAK2/STAT3 pathway activation.

2. Materials and Methods
2.1 Animals

This study was approved by the institutional guidelines of the Animal Care and Use Committee of Children’s Hospital of Chongqing Medical University, China and was conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult and neonatal C57/BL6 mice were housed in a SPF environment with a 12-h light-dark cycle, and were allowed access to feed and tap water ad libitum. Within 12 hours of birth, pups from multiple litters were pooled and randomly distributed to experimental groups.

2.2 Establishment of Neonatal ARDS Model

The neonatal ARDS model of mouse was conducted according to the previous experience, with some adjustments [25]. C57BL/6 mouse pups (day of life 6) were randomly divided into three groups: the control group, the LPS-induced ARDS group, and the ARDS+heparin group. Pups of the LPS-induced ARDS group received intraperitoneal injection of 10 mg/kg of LPS Escherichia coli O111:B4; Sigma, St. Louis, MO, USA) diluted in sterile saline to a final volume of 20 µL; For the control group, pups were given an equal volume of sterile saline via intraperitoneal injection; and pups of the ARDS+heparin group were treated with unfractionated heparin (Macklin Biochemical Co., Ltd , Shanghai, China) via subcutaneous injection at 400 IU/kg per pup 30 minutes prior to LPS, based on the previous studies [26, 27]. The mice were allowed to recover overnight. All mice were euthanized by decapitation at 24 h post-LPS administration, and the lungs and blood samples were harvested for histological and biochemical assessments.

2.3 Survival Analysis

A total of 30 mouse pups were grouped and treated as above (n = 10). The number of dead pups in each group was observed and recorded every six hours for a total of 24 hours. The mortality during the observation period was calculated.

2.4 Lung Histology

Fresh postnatal lungs on postnatal day (PND) 6 were harvested and fixed with 4% paraformaldehyde and paraffin embedded for histology. The lungs were then processed to obtain 5 µm thick paraffin sections, followed by staining with hematoxylin and eosin (H&E). Histological characteristic was evaluated by a pathologist blinded to the experiment. The lung inflammatory score was categorized according to the sum of the score for neutrophil infiltration, alveolar congestion, hemorrhage, and thickness of alveolar wall/hyaline membrane formation [28].

2.5 Measurement of Myeloperoxidase (MPO) Level in Lung Tissues

Commonly used to evaluate the degree of neutrophil accumulation in lungs [29, 30], MPO concentration was detected in our study. Briefly, lung tissues were excised after 24 h of LPS-administration, and were homogenized and dissolved in extraction buffer for the analysis of MPO concentration using a commercially available mouse MPO ELISA kit (Solarbio life sciences, Beijing, China). Absorbance was determined at 450 nm.

2.6 Measurement of Extracellular Histones and Cytokines

We first measured the extracellular histones of serum using a histone H4 detection kit (USCN, Wuhan, China). We then measured a panel of multiple cytokines of serum using a commercially available multiplex immunoassay (MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel, Millipore, Burlington, MA, USA), which can simultaneously quantify the following five cytokines: IFN-γ, TNF-α, IL-1β, IL-6, and IL-10. The samples were processed in duplicate.

2.7 Quantitative RT-PCR Analysis

Extraction of total RNA from the lung tissue was conducted using SteadyPure Quick RNA Extraction Kit (Accurate Biotechnology, Hunan, China). The extracted RNA was synthesized into cDNA using reverse transcription PCR (Accurate Biotechnology, Changsha, Hunan, China). The SYBR Green kit (SYBR Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, Hunan, China)) with specific primers for JAK2 and STAT3 (Accurate Biotechnology, Hunan, China) was used to perform real time quantitative PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the input mRNA levels (JAK2, STAT3) as an endogenous housekeeping gene. Primers used for quantitative PCR include JAK2f: 5′-CAACCTCAGCGGGACTAAGA-3′ and JAK2r: 5′-GGGGCAGCATTTGGTAAACT-3′. STAT3f: 5′-ATGCTTGTCGGTTGGAGGTG-3′ and STAT3r: 5′-GGGAGGGAGTAGGGTGATGA-3′. The results are shown as the mean 2-Δ⁢Δ⁢Ct ± SD.

2.8 Western Blot Analysis of Lung Tissue

Extraction of total protein from the lung tissue was conducted using RIPA lysis buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS) with extra added phenylmethylsulfonyl fluoride (PMSF) and a phosphatase inhibitor (Beyotime Biotechnology, Beijing, China). Protein quantification was detected using a BCA Protein Assay Kit (Beyotime Biotechnology, Beijing, China). Next, protein was separated on 7.5% SDS-PAGE gels and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). After incubating with primary antibodies against JAK2 (abcam, Cambridge, CA, USA), STAT3 (abcam, Cambridge, CA, USA), phospho-JAK2 (Y1007/1008) (abcam, Cambridge, CA, USA), phospho-STAT3 (Y705) (abcam, Cambridge, CA, USA), and β-actin (proteintech, Wuhan, China) overnight at 4 °C, the protein antibody immune complexes were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature. The Bio-Rad ChemiDoc™ Touch imaging system was used for exposure imaging and the images were analyzed using Image J software, version 1.51 (NIH, Bethesda, MA, USA).

2.9 Statistics

GraphPad prism 8.3.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to analyze the data. All data were expressed as the mean ± SEM (standard error of mean). One-way analysis of variance (ANOVA) was used for multiple comparison of the three groups. p values < 0.05 were considered significant.

3. Results
3.1 Unfractionated Heparin Improved Survival Rate in LPS-Induced ARDS in Neonatal Mice

The survival of mouse pups were observed for 24 consecutive hours, and the 24-hour survival rate was calculated. Results in Fig. 1 showed that mice survival rate in the ARDS group (30%) was significantly reduced than the control group (100%), while the decrease in survival rate was significantly increased after pharmacological inhibition with unfractionated heparin.

Fig. 1.

Unfractionated heparin improves the survival rate of neonatal ARDS mice. The survival rate was analyzed using the log-rank test. **p < 0.01 versus the control group; #p < 0.05 versus the ARDS group.

3.2 Unfractionated Heparin Alleviated Lung Histopathological Changes in LPS-Induced ARDS in Neonatal Mice

To examine the protective effect of unfractionated heparin against LPS-induced neonatal ARDS, pathological analysis was performed for each mouse and the lung injury score was calculated. As shown in Fig. 2a, multifocal alveolar hemorrhage, disruption of alveolar wall, and massive infiltration of inflammatory cells were observed in mice of the ARDS group, whereas injected with unfractionated heparin alleviated LPS induced damages. In addition, administration of LPS dramatically increased lung injury score (Fig. 2b), which was significantly reduced after pharmacological inhibition with unfractionated heparin.

Fig. 2.

Unfractionated heparin ameliorates the morphological characteristics of LPS-induced ARDS. Heparin (400 IU/kg) was administered 30 minutes before LPS administration. (a) Representative pictures of H-E stained lung tissues, magnification (×20) in the control group; the ARDS group; the ARDS+heparin group. (b) Lung injury scores in all groups. Data are means ± SEM, n = 10 per group. ****p < 0.0001 versus the control group; ####p < 0.0001 versus the ARDS group.

3.3 Unfractionated Heparin Reduced Lung MPO Level in LPS-Induced ARDS in Neonatal Mice

To investigate the infiltration and accumulation of neutrophils in the lung tissues, analysis of MPO concentration was detected according to the manufacturer’s instruction. As shown in Fig. 3, significant increase of the lung MPO concentration was observed in the ARDS group. While the increase in MPO concentration was significantly decreased after pharmacological inhibition with unfractionated heparin. These data suggested that unfractionated heparin can relieve lung inflammation in neonatal ARDS mice.

Fig. 3.

Unfractionated heparin reduced the expression of MPO in neonatal ARDS mice. Lung tissues were collected at 24 h after LPS or normal saline administration. Data are means ± SEM, n = 8–10 per group. ****p < 0.0001 versus the control group; ###p < 0.001 versus the ARDS group.

3.4 Unfractionated Heparin Suppressed Extracellular Histones in LPS-Induced ARDS in Neonatal Mice

Studies have shown that extracellular histones are inflammatory mediators involved in the pathogenesis of ARDS [8, 9, 31]. To determine whether unfractionated heparin could inhibit the release of extracellular histones, the histone H4 level in serum was detected by ELISA. We found that after lung injury, the level of histone H4 was significantly increased in neonatal ARDS mice, and unfractionated heparin significantly reduced the levels of histone H4 in serum (Fig. 4).

Fig. 4.

Unfractionated heparin reduced the expression of extracellular histones in serum of neonatal ARDS mice. Blood samples were collected at 24 h after LPS or normal saline administration. Data are means ± SEM, n = 6 per group. ***p < 0.001 versus the control group; ####p < 0.0001 versus the ARDS group.

3.5 Unfractionated Heparin Regulated the Cytokine Expression in LPS-Induced ARDS in Neonatal Mice

To confirm the role of unfractionated heparin in the regulation of inflammatory response in neonatal ARDS mice, we measured the related inflammatory cytokines of IFN-γ, IL-1β, IL-6, TNF-α, and IL-10 in serum. As shown in Fig. 5, unfractionated heparin significantly diminished the levels of proinflammatory cytokines of IFN-γ, TNF-α, IL-1β, and IL-6, while significantly augmented the level of anti-inflammatory cytokine of IL-10, as compared with the ARDS group.

Fig. 5.

Unfractionated heparin diminished the expression of pro-inflammatory cytokines and augmented the expression of anti-inflammatory cytokine in the serum of neonatal ARDS mice. Blood samples were collected at 24 h after LPS or normal saline administration. (a) IFN-γ. (b) IL-1β. (c) IL-6. (d) TNF-α. (e) IL-10. Data are means ± SEM, n = 6–8 per group. ****p < 0.0001 versus the control group; ####p < 0.0001 versus the ARDS group.

3.6 Unfractionated Heparin Inhibited the Activation of JAK2/STAT3 Signaling Pathway in LPS-Induced ARDS in Neonatal Mice

As shown in Fig. 6a,b, the mRNA expressions of JAK2 and STAT3 in the ARDS group was significantly up-regulated compared with that in the control group, but were reduced in presence of unfractionated heparin, respectively. Western blot analysis also showed that the protein expressions of phosphorylated JAK2 (p-JAK2) (Y1007/1008) and p-STAT3 (Y705) in the ARDS group were both significantly increased as compared to that in the control group (Fig. 7a). When unfractionated heparin was applied, the protein expression of p-JAK2 (Y1007/1008) was down-regulated (Fig. 7b), but no change on the expression of JAK2 (Fig. 7c). Similarly, the protein expression of p-STAT3 (Y705) (Fig. 7d) but no STAT3 (Fig. 7e) was significantly up-regulated, while the increased expression of p-STAT3 (Y705) was significantly decreased after administration of unfractionated heparin (Fig. 7d), but no change on the expression of STAT3 (Fig. 7e). These results demonstrated that unfractionated heparin may relieve the inflammatory response during ARDS via inactivation of the JAK2/STAT3 signaling pathway.

Fig. 6.

Expression levels of JAK2/STAT3 signaling pathway in lung tissues of neonatal ARDS mice by qRT-PCR (a,b). Lung tissues were collected at 24 h after LPS or normal saline administration. Data are means ± SEM, n = 6–7 per group. ****p < 0.0001 versus the control group; ####p < 0.0001 versus the ARDS group.

Fig. 7.

Expression levels of JAK2/STAT3 signaling pathway in lung tissues of neonatal ARDS mice by western blot (a–e). Lung tissues were collected at 24 h after LPS or normal saline administration. Data are means ± SEM, n = 7 per group. ****p < 0.0001 versus the control group; ###p < 0.001, ####p < 0.0001 versus the ARDS group.

4. Discussion

Plenty of studies have shown that LPS is a perfect component to establish animal models of ARDS [32]. In the current study, we found that intraperitoneal injection of LPS to the six-day-old neonatal C57BL/6 mice resulted in the destruction of alveolar structure, which was in accordance with the previous research [24].

Possessing high affinity for antithrombin and a large number of heparin-binding proteins such as coagulation and fibrinolytic factors, chemokines/cytokines, histone-like protein, extracellular matrix proteins, and immune response mediators, heparin exits both anticoagulant and anti-inflammatory properties [33, 34]. However, the mechanisms by which heparin exerts its therapeutic effects on ARDS have remained poorly understood. In this study, we found that unfractionated heparin improved the survival rate, attenuated LPS-induced physiological and hematological changes, as evidenced by attenuated pulmonary pathologic damages, reduced levels of extracellular histones and pro-inflammatory cytokines, increased level of anti-inflammatory cytokine, and dramatically reduction of neutrophil infiltration in the lungs as assessed by MPO in LPS-induced ARDS in neonatal mice. These data indicate that unfractionated heparin may protect lungs from the inflammatory effects of LPS-induced neonatal ARDS by altering the inflammatory profile.

In animal models and patients of ARDS, extracellular histones have been proven to be associated with damages [35, 36]. Study showed that heparin/low molecular weight heparin exerted a positive effect on mortality in COVID-19 patients by neutralizing the extracellular histones [37]. And multiple studies reported that heparin may neutralize extracellular histones, thus reducing the toxicity of extracellular histones [38, 39]. Contrast to heparin that has high negative charges, histones is rich in positive charges resulting in strong affinity toward heparin [38]. By forming a non-toxic complex through interaction of heparin and histones to prevent histone interactions with endothelial cells and platelets, which could protect against thrombocytopenia, tissue damage, and death induced by histones [40, 41]. In the present study, a marked increase of extracellular histones in the serum of neonatal ARDS mice was observed than the controls, while unfractionated heparin significantly reduced the level of extracellular histones, suggesting that extracellular histones mediate in the systematic inflammatory changes in neonatal ARDS, and unfractionated heparin might exert its anti-inflammatory property by binding to histones.

It is well demonstrated that inflammatory response plays profound roles in ARDS [5]. Heparin has been reported to be able to bind to the vast majority of chemokines and cytokines [42]. In animal models, heparin could decrease the production of pro-inflammatory factors [43]. IL-6 is a pleiotropic cytokine considered to play a critical role in inflammation [44]. By binding to IL-6 receptor on the cell surface, IL-6 associates with the signal transducing β-receptor gp130 to promote phosphorylation of JAK2 [45, 46]. IL-1β was reported to increase the expression of IL-6 [47, 48, 49]. IFN-γ participates in a variety of inflammatory response [50] and was reported to activate JAK2/STAT3 signaling cascade in previous studies [51, 52]. Known as a pro-inflammatory cytokine, TNF-α is related to the aggregation of various chemokines to cause leucocyte aggregation [53]. Some investigations indicated that hypersection of TNF-α could activate the JAK2/STAT3 signaling pathway, which finally leads to inflammation and apoptosis [54, 55, 56]. As a potent anti-inflammatory cytokine, IL-10 plays an important role in the initiation and maintenance of immune tolerance and homeostasis [57]. IL-10 could activate STAT3 to exert its inhibitory effects on activated immune response [58]. Besides, IL-10 is also involved in the activation of JAK2 [59]. Consistent with previous studies, we observed that inflammatory cytokines of IFN-γ, IL-1β, IL-6, TNF-α, and IL-10, and protein expressions of p-JAK2 (Y1007/1008) and p-STAT3 (Y705) were increased in LPS-induced neonatal ARDS mice, while the up-regulated pro-inflammatory cytokines of IL-6, IFN-γ, IL-1β, IL-6, and TNF-α were reversed by unfractionated heparin, accompanied by an increase of the anti-inflammatory cytokine of IL-10, meanwhile, phosphorylation of JAK2 and STAT3 was blocked.

Growing evidence suggests that the JAK2/STAT3 signaling involves in lung injury and other pulmonary pathophysiology [60, 61, 62]. The phosphorylation of JAK2 subsequently leads to the phosphorylation and dimerization of STAT3 [63]. Activation of STAT3 requires phosphorylation of the Y705 residue, which is constitutively hyperphosphorylated and then translocated into nucleus where STAT3 binds to specific DNA response elements and regulates target gene transcription [64]. Piao et al. [21] showed inflammation and oxidative stress in mice with lung injury were significantly attenuated by inhibiting the JAK2/STAT3 pathway. Zhao et al. [65] demonstrated that bleomycin-induced acute lung injury was also alleviated by inhibiting the JAK2/STAT3 signaling pathway. In the present study, the results showed that unfractionated heparin downregulated the levels of mRNA expression of JAK2 and STAT3 and the protein expression of p-JAK2 (Y1007/1008) and p-STAT3 (Y705) induced by LPS. The JAK2/STAT3 signaling pathway can modulate gene expression in many biological pathways such as cell survival, proliferation, and inflammation [66]. And the suppression of JAK2/STAT3 signaling pathway by reducing the mRNA and phosphorylation expression of JAK2 and STAT3 with no changed total expressions has been reported to attenuate the inflammatory response in lung disease [21, 62], which is consistent with our results. Possible reason is that the transcription activation might be regulated by interaction of JAK2/STAT3 with other regulatory factors owing to phosphorylation. However, the reason of no changed total expressions of JAK2 and STAT3 among the three groups is not clear because remarkable decrease of p-JAK2 (Y1007/1008) and p-STAT3 (Y705) in the heparin intervention group were observed, which should be explored in the further research.

There are some limitations in our study. Firstly, ARDS is a complex disorder that is difficult to reflect in a simplified model such as the LPS model. Secondly, we only identified the role of unfractionated heparin in LPS-induced neonatal ARDS, whereas its role in other neonatal ARDS models (such as aspiration-induced ARDS) requires further study. If the beneficial efficacy is consistently determined, these preclinical results should be transferred to clinical trials to further assess the effects of unfractionated heparin on ARDS of neonates.

5. Conclusions

In conclusion, our experimental results demonstrated that unfractionated heparin significantly improved the survival rate, attenuated the lung architecture damage, reduced the concentration of MPO and extracellular histones, diminished the levels of proinflammatory cytokines, and increased the anti-inflammatory cytokine of IL-10 as compared to the ARDS group. Consistently, PCR data and western blot results indicated that the gene and protein expression levels of phosphorylated JAK2/STAT3 also increased in the ARDS group and decreased in the heparin intervention group. These results suggested that unfractionated heparin may alleviate LPS-induced neonatal ARDS by reducing inflammatory response and inhibition of JAK2/STAT3 pathways. Which provides a new perspective for the study of its molecular mechanism.

Availability of Data and Materials

The raw data supporting the conclusions of this article will be made available by the corresponding author YS, without undue reservation.

Author Contributions

YS and JX designed the study. JX performed the experiment. QA and LB analyzed and interpreted the data. JX drafted the manuscript. All authors reviewed and approved the manuscript.

Ethics Approval and Consent to Participate

This study was approved by the Review and Ethics committee of the Children’s Hospital of Chongqing Medical University (Ethic Approval Number: CHCMU-IACUC20220429009).

Acknowledgment

Dr Xiong thank Mr. Bo Wang for his help and support during the experiment.

Funding

This study was supported by grants of NCRCCHD-2020-GP-03 from the National Clinical Research Center for Child Health and Disorders (Republic of China, Chongqing) and CSTC2021jscx-gksb-N0015 from the Ministry of Science and Technology (Republic of China, Chongqing).

Conflict of Interest

The authors declare no conflict of interest. YS is serving as Guest Editor of this journal. We declare that YS had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to GP.

References
[1]
Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967; 2: 319–323.
[2]
De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity. The Lancet. Respiratory Medicine. 2017; 5: 657–666.
[3]
Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. The New England Journal of Medicine. 2017; 377: 562–572.
[4]
Wu H, Hong X, Qu Y, Liu Z, Zhao Z, Liu C, et al. The value of oxygen index and base excess in predicting the outcome of neonatal acute respiratory distress syndrome. Jornal De Pediatria. 2021; 97: 409–413.
[5]
Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annual Review of Pathology. 2011; 6: 147–163.
[6]
Matt U, Warszawska JM, Bauer M, Dietl W, Mesteri I, Doninger B, et al. Bbeta(15-42) protects against acid-induced acute lung injury and secondary pseudomonas pneumonia in vivo. American Journal of Respiratory and Critical Care Medicine. 2009; 180: 1208–1217.
[7]
Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. The Cochrane Database of Systematic Reviews. 2019; 7: CD004477.
[8]
Zhang Y, Wen Z, Guan L, Jiang P, Gu T, Zhao J, et al. Extracellular histones play an inflammatory role in acid aspiration-induced acute respiratory distress syndrome. Anesthesiology. 2015; 122: 127–139.
[9]
Lv X, Wen T, Song J, Xie D, Wu L, Jiang X, et al. Extracellular histones are clinically relevant mediators in the pathogenesis of acute respiratory distress syndrome. Respiratory Research. 2017; 18: 165.
[10]
Corrigan JJ. Heparin therapy in bacterial septicemia. The Journal of Pediatrics. 1977; 91: 695–700.
[11]
Wang ZY, Wu SN, Zhu ZZ, Yang BX, Zhu X. Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats. Chinese Medical Journal. 2013; 126: 318–324.
[12]
Dixon B, Smith RJ, Campbell DJ, Moran JL, Doig GS, Rechnitzer T, et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine. 2021; 9: 360–372.
[13]
Mu E, Ding R, An X, Li X, Chen S, Ma X. Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-β/Smad signaling pathway. Thrombosis Research. 2012; 129: 479–485.
[14]
Anastase-Ravion S, Carreno M, Blondin C, Ravion O, Champion J, Chaubet F, et al. Heparin-like polymers modulate proinflammatory cytokine production by lipopolysaccharide-stimulated human monocytes. Journal of Biomedical Materials Research. 2002; 60: 375–383.
[15]
Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. British Journal of Haematology. 2006; 133: 62–67.
[16]
O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109: S121–S131.
[17]
Liu Z, Gan L, Zhou Z, Jin W, Sun C. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology. 2015; 220: 947–953.
[18]
Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004; 117: 699–711.
[19]
Chatti K, Farrar WL, Duhé RJ. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry. 2004; 43: 4272–4283.
[20]
Sosonkina N, Starenki D, Park J. The Role of STAT3 in Thyroid Cancer. Cancers. 2014; 6: 526–544.
[21]
Piao X, Zou Y, Sui X, Liu B, Meng F, Li S, et al. Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress. Oxidative Medicine and Cellular Longevity. 2019; 2019: 9659757.
[22]
Xu G, Wan H, Yi L, Chen W, Luo Y, Huang Y, et al. Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-κB and JAK2/STAT3 inhibition. European Journal of Pharmacology. 2021; 908: 174349.
[23]
Cao F, Tian X, Li Z, Lv Y, Han J, Zhuang R, et al. Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice. Frontiers in Pharmacology. 2020; 11: 306.
[24]
Xu S, Pan X, Mao L, Pan H, Xu W, Hu Y, et al. Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation. Cell Communication and Signaling. 2020; 18: 104.
[25]
Ying L, Alvira CM, Cornfield DN. Developmental differences in focal adhesion kinase expression modulate pulmonary endothelial barrier function in response to inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2018; 315: L66–L77.
[26]
Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. British Journal of Pharmacology. 2005; 146: 333–343.
[27]
Li L, Yu S, Fu S, Ma X, Li X. Unfractionated heparin inhibits histone-mediated coagulation activation and thrombosis in mice. Thrombosis Research. 2020; 193: 122–129.
[28]
Cao C, Yin C, Shou S, Wang J, Yu L, Li X, et al. Ulinastatin Protects Against LPS-Induced Acute Lung Injury By Attenuating TLR4/NF-κB Pathway Activation and Reducing Inflammatory Mediators. Shock. 2018; 50: 595–605.
[29]
Pulli B, Ali M, Forghani R, Schob S, Hsieh KLC, Wojtkiewicz G, et al. Measuring myeloperoxidase activity in biological samples. PLoS ONE. 2013; 8: e67976.
[30]
Fan H, Zingarelli B, Peck OM, Teti G, Tempel GE, Halushka PV, et al. Lipopolysaccharide- and gram-positive bacteria-induced cellular inflammatory responses: role of heterotrimeric Galpha(i) proteins. American Journal of Physiology. Cell Physiology. 2005; 289: C293–C301.
[31]
Lefrançais E, Looney MR. Neutralizing Extracellular Histones in Acute Respiratory Distress Syndrome. A New Role for an Endogenous Pathway. American Journal of Respiratory and Critical Care Medicine. 2017; 196: 122–124.
[32]
Xu J, Qu J, Cao L, Sai Y, Chen C, He L, et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. The Journal of Pathology. 2008; 214: 472–481.
[33]
Young E. The anti-inflammatory effects of heparin and related compounds. Thrombosis Research. 2008; 122: 743–752.
[34]
Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of Heparin and Related Drugs. Pharmacological Reviews. 2016; 68: 76–141.
[35]
Jiang P, Jin Y, Sun M, Jiang X, Yang J, Lv X, et al. Extracellular histones aggravate inflammation in ARDS by promoting alveolar macrophage pyroptosis. Molecular Immunology. 2021; 135: 53–61.
[36]
Zhang Y, Zhao J, Guan L, Mao L, Li S, Zhao J. Histone H4 aggravates inflammatory injury through TLR4 in chlorine gas-induced acute respiratory distress syndrome. Journal of Occupational Medicine and Toxicology. 2020; 15: 31.
[37]
Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020; 59: 102969.
[38]
Wildhagen KCAA, García de Frutos P, Reutelingsperger CP, Schrijver R, Aresté C, Ortega-Gómez A, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014; 123: 1098–1101.
[39]
Wang F, Zhang N, Li B, Liu L, Ding L, Wang Y, et al. Heparin defends against the toxicity of circulating histones in sepsis. Frontiers in Bioscience-Landmark. 2015; 20: 1259–1270.
[40]
Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011; 118: 3708–3714.
[41]
Freeman CG, Parish CR, Knox KJ, Blackmore JL, Lobov SA, King DW, et al. The accumulation of circulating histones on heparan sulphate in the capillary glycocalyx of the lungs. Biomaterials. 2013; 34: 5670–5676.
[42]
Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, et al. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. American Journal of Respiratory Cell and Molecular Biology. 2003; 28: 464–472.
[43]
Huang X, Han S, Liu X, Wang T, Xu H, Xia B, et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. Experimental and Therapeutic Medicine. 2020; 19: 913–922.
[44]
Kishimoto T. Interleukin-6: from basic science to medicine–40 years in immunology. Annual Review of Immunology. 2005; 23: 1–21.
[45]
Zanders L, Kny M, Hahn A, Schmidt S, Wundersitz S, Todiras M, et al. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting. Journal of Cachexia, Sarcopenia and Muscle. 2022; 13: 713–727.
[46]
Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn’s disease. The Journal of Biological Chemistry. 2003; 278: 16777–16781.
[47]
Huang N, Kny M, Riediger F, Busch K, Schmidt S, Luft FC, et al. Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy. Intensive Care Medicine Experimental. 2017; 5: 3.
[48]
Langhans C, Weber-Carstens S, Schmidt F, Hamati J, Kny M, Zhu X, et al. Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy. PLoS ONE. 2014; 9: e92048.
[49]
Hahn A, Kny M, Pablo-Tortola C, Todiras M, Willenbrock M, Schmidt S, et al. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. Journal of Cachexia, Sarcopenia and Muscle. 2020; 11: 103–119.
[50]
Kanoh H, Ishitsuka A, Fujine E, Matsuhaba S, Nakamura M, Ito H, et al. IFN-γ Reduces Epidermal Barrier Function by Affecting Fatty Acid Composition of Ceramide in a Mouse Atopic Dermatitis Model. Journal of Immunology Research. 2019; 2019: 3030268.
[51]
Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. International Journal of Cancer. 2018; 143: 931–943.
[52]
Aota K, Yamanoi T, Kani K, Ono S, Momota Y, Azuma M. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells. Inflammation. 2021; 44: 206–216.
[53]
Choi E, Lee S, Kim H, Singh TSK, Choi JK, Choi HG, et al. Suppression of dust mite extract and 2,4-dinitrochlorobenzene-induced atopic dermatitis by the water extract of Lindera obtusiloba. Journal of Ethnopharmacology. 2011; 137: 802–807.
[54]
Long Q, Wu Y, He L, Ding L, Tan A, Shi H, et al. Suan-Zao-Ren Decoction ameliorates synaptic plasticity through inhibition of the Aβ deposition and JAK2/STAT3 signaling pathway in AD model of APP/PS1 transgenic mice. Chinese Medicine. 2021; 16: 14.
[55]
Chen X, Nie X, Mao J, Zhang Y, Yin K, Jiang S. Perfluorooctanesulfonate induces neuroinflammation through the secretion of TNF-α mediated by the JAK2/STAT3 pathway. Neurotoxicology. 2018; 66: 32–42.
[56]
Li X, Ma Q, Jiang Y, Bai X, Yan Z, Liu Q, et al. Xiaoyaosan exerts anxiolytic-like effects by down-regulating the TNF-α/JAK2-STAT3 pathway in the rat hippocampus. Scientific Reports. 2017; 7: 353.
[57]
Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Critical Reviews in Immunology. 2012; 32: 23–63.
[58]
Karimollah A, Hemmatpur A, Hosseini N, Manshadi MD. Tropisetron balances immune responses via TLR2, TLR4 and JAK2/STAT3 signalling pathway in LPS-stimulated PBMCs. Basic & Clinical Pharmacology & Toxicology. 2021; 128: 669–676.
[59]
Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012; 119: 2844–2853.
[60]
Fan S, He J, Yang Y, Wang D. Intermedin Reduces Oxidative Stress and Apoptosis in Ventilator-Induced Lung Injury via JAK2/STAT3. Frontiers in Pharmacology. 2022; 12: 817874.
[61]
Kong F, Sun Y, Song W, Zhou Y, Zhu S. MiR-216a alleviates LPS-induced acute lung injury via regulating JAK2/STAT3 and NF-κB signaling. Human Cell. 2020; 33: 67–78.
[62]
Zhang L, Lu P, Guo X, Liu T, Luo X, Zhu Y. Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer. Inflammation Research. 2019; 68: 751–760.
[63]
Owais K, Huang T, Mahmood F, Hubbard J, Saraf R, Bardia A, et al. Cardiopulmonary Bypass Decreases Activation of the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway in Diabetic Human Myocardium. The Annals of Thoracic Surgery. 2015; 100: 1636–1645.
[64]
Tai W, Cheng A, Shiau C, Huang H, Huang J, Chen P, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Journal of Hepatology. 2011; 55: 1041–1048.
[65]
Zhao X, Zhao B, Zhao Y, Zhang Y, Qian M. Protective effect of anisodamine on bleomycin-induced acute lung injury in immature rats via modulating oxidative stress, inflammation, and cell apoptosis by inhibiting the JAK2/STAT3 pathway. Annals of Translational Medicine. 2021; 9: 859.
[66]
Grote K, Luchtefeld M, Schieffer B. JANUS under stress–role of JAK/STAT signaling pathway in vascular diseases. Vascular Pharmacology. 2005; 43: 357–363.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share
Back to top
Front. Biosci. (Landmark Ed) Print ISSN 2768-6701 Electronic ISSN 2768-6698
Disclaimer
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept